Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Scott D. Sandell currently holds 106,230 shares of Adaptimmune Therapeutics PLC (ADAP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Scott D. Sandell has been a net seller of ADAP stock. They have purchased $641.6M and sold $1.1B worth of shares.
Scott D. Sandell's most recent insider trade was on Jun 11, 2026, when they sold 34,260 shares at $0.00 per share.
Scott D. Sandell serves as Executive at Adaptimmune Therapeutics PLC (ADAP). They have executed 982 insider transactions totaling $1.7B over their tenure at the company.
Scott D. Sandell holds the position of Executive at Adaptimmune Therapeutics PLC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Scott D. Sandell has shown a selling trading pattern, with $641.6M in total purchases and $1.1B in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Scott D. Sandell was on Sep 16, 2024, when they purchased $8.0M worth of MBX shares. This transaction involved 500,000 shares at $16.00 per share.
Scott D. Sandell currently owns 106,230 shares of Adaptimmune Therapeutics PLC (ADAP), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Scott D. Sandell's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Scott D. Sandell has 982 Form 4 filings on record as an insider at Adaptimmune Therapeutics PLC.
Set alerts for Scott D. Sandell and 40,000+ other insiders.